Get the Stockscreener App
0.982
5.59%
0.052
Prelude Therapeutics Inc stock is traded at $0.982, with a volume of 10,269.
It is up +5.59% in the last 24 hours and up +25.05% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$0.93
Open:
$0.95
24h Volume:
10,269
Relative Volume:
0.07
Market Cap:
$54.77M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.5517
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
+16.61%
1M Performance:
+25.05%
6M Performance:
-13.86%
1Y Performance:
-83.04%
1-Day Range:
$0.93
$0.98
1-Week Range:
$0.84
$1.02
52-Week Range:
$0.6101
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
0.97 | 52.51M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.05 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.88 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.80 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.91 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.96 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Buy Signal for Prelude Therapeutics Incorporated Stock Key Technical Indicators to WatchMarket Forecast Summary Over Multi-Year Period - Newser
SRx Health Solutions Inc. recovery potential after sell offPrice Action Summary and Entry Strategy Guide - Newser
Using data models to predict Prelude Therapeutics Incorporated stock movementFree Growth Focused Entry Plan Suggestions - Newser
What is the dividend policy of Prelude Therapeutics Incorporated stockBuild your wealth with consistent stock growth - jammulinksnews.com
What makes Prelude Therapeutics Incorporated stock price move sharply Entry Timing Tracker with Alert Accuracy - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionPredictive Screener for Daily Trade Watch - Newser
Is it the right time to buy Prelude Therapeutics Incorporated stockDiscover stocks with strong growth potential - jammulinksnews.com
Prelude Therapeutics Incorporated Stock Performance After Earnings: Historical InsightsWeekly Big Movers - Newser
What makes Prelude Therapeutics Incorporated stock price move sharplyFree Access to Community - metal.it
Prelude Therapeutics (NASDAQ:PRLD) Trading 2% Higher – Time to Buy? - Defense World
What drives Prelude Therapeutics Incorporated stock priceUnmatched profit growth - PrintWeekIndia
Is Prelude Therapeutics Incorporated a good long term investmentSkyrocketing investment returns - PrintWeekIndia
What analysts say about Prelude Therapeutics Incorporated stockRapid wealth accumulation - Autocar Professional
Will Prelude Therapeutics Incorporated stock split in the near futureExplosive trading opportunities - jammulinksnews.com
Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study - TipRanks
Prelude Therapeutics Incorporated Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com
what makes prelude therapeutics incorporated stock price move sharplyFree Investment Community - Newser
Is Prelude Therapeutics Incorporated stock a good hedge against inflation10x Return With Managed Risk - Newser
How Prelude Therapeutics Incorporated stock performs during market volatilityFree Smart Investment Opportunities - Newser
Prelude Therapeutics’ PRT7732 Study: A Potential Game-Changer for SMARCA4 Mutations - TipRanks
Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors - TipRanks
Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study - TipRanks
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prelude Therapeutics Inc Stock (PRLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
0.43%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):